LPCN Latest Press Releases

-- October 7, 2026 --

Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy PRNewswire 8:01 AM

-- September 14, 2026 --

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression PRNewswire 8:00 AM

-- September 10, 2026 --

Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference PRNewswire 8:01 AM

-- August 4, 2026 --

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 PRNewswire 8:00 AM

-- August 3, 2026 --

Lipocine Appoints Michael J. Grissinger to Board of Directors PRNewswire 8:00 AM

-- June 4, 2026 --

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 PRNewswire 8:00 AM

-- May 19, 2026 --

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting PRNewswire 8:00 AM

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer Globe Newswire 4:00 AM

-- May 18, 2026 --

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase PRNewswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software